22JPM

Hexima Limited to Participate at ACCESS CHINA Biotech Forum

By Yafo Life Sciences

December 26th, 2021 (Shanghai) — We are glad to announce that Michael Aldridge, the CEO of Hexima Limited, has been invited to showcase at ACCESS CHINA Biotech Forum during Jan 4th – Jan13th. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.

If you are interested in listening to the live event, please register at https://biotochina.org/register/

About Hexima Limited

Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company. Its lead product candidate, pezadeftide, is a potential new topical prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting a 117 patient phase IIb clinical trial.

About the speaker

CEO Peplin, sold to Leo Pharma in 2009 for $300M: SVP Corporate Strategy Questcor, sold to Mallinckrodt in 2014 for $5.6B: SVP Corporate & Strategic Development Codexis, $357M partnership with Nestle in PKU in 2017

About ACCESS CHINA

ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/


Contact US

Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum

For more information, please contact:

Wendi Xiang

Wxiang@yafocapital.com